Q-omics provides the consensus-scored DHRS1 profile across patient tissues and cancer cell-line models. DHRS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DHRS1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, DHRS1 RNA expression shows 18,908 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KICH, and ACC as cancer lineages where DHRS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS1 survival associations across molecular data types. DHRS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS1 RNA expression–survival associations across cancer types. High DHRS1 expression shows unfavorable associations in KICH, ACC and HNSC, but favorable associations in MESO, SCLC and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DHRS1 RNA expression.
This table summarizes DHRS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DHRS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS1 shows lower tumor expression in KICH, LIHC, KIRC, COAD and CHOL and higher tumor expression in THCA. The KICH box plot shows higher DHRS1 RNA expression in normal versus tumor tissue (log2 FC = −1.321, t-test p < 0.001).
This table shows molecular features associated with DHRS1 in patient tissues and cancer cell lines. In patient samples, DHRS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
